Arcutis Biotherapeutics(ARQT)

Focus: Arcutis is a public dermatology-focused biotech company built on topical PDE4 inhibitor reformulations, currently generating revenue primarily from ZORYVE (roflumilast) launched in 2024. The company operates at mid-cap scale with ~$60M in FY2025 revenue and is expanding its portfolio across multiple skin conditions.

Dermatology

Profile data last refreshed 35m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

7+4 this month

Stable — net +4 jobs in 30d

7 added, 3 removed. Backfill posture.

Should You Work at Arcutis Biotherapeutics?

AI assessment

High-growth opportunity with clinical validation (ZORYVE launch success) but elevated financial volatility and dependency on pipeline expansion; best for candidates with risk tolerance and belief in dermatology market.

Why Work Here

First-mover advantage in topical PDE4 space: ZORYVE achieved $60M revenue in first full year (FY2025), demonstrating strong market traction and dermatologist adoption.

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$60M

Key Products

ZORYVE

Not specified

$7M Part D

GROWTH15.7yr

Help build intelligence for Arcutis Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep pipeline with 14 programs across 4 phases targeting high-prevalence indications (plaque psoriasis, atopic dermatitis, seborrheic dermatitis, chronic hand eczema, vitiligo) — clear path to expand beyond single-product dependency.

Significant commercial inflection: company is actively hiring in Commercial (3 roles), signaling confidence in ZORYVE expansion and preparing for Phase 3 catalysts in psoriasis and seborrheic dermatitis.

Watch Out For

Extreme cash burn despite early revenue: R&D spending of $111M on only $60M revenue (186% R&D intensity) and FY2024 net loss of -$311M creates medium-term funding uncertainty despite current $71M cash position.
Single-product revenue concentration at 100% creates execution risk; pipeline programs are early-stage (majority Phase 1/2) with 2042 and 2037 LOE dates suggesting limited near-term diversification.

Generated by Claude from Arcutis Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Lead commercial product with roflumilast foam formulation; PDE4 inhibitor approved in growth phase with 18-year exclusivity window.

ZORYVE

Not specified

PEAK10.7yr

Secondary roflumilast indication or formulation in peak lifecycle with 13-year patent protection; Part D spending data not available.

Pipeline & Clinical Trials

ARQ-154 Foam 0.3%

Psoriasis

Phase 1

Clinical Trials (1)

NCT07340216Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Phase 1

ARQ-234

Atopic Dermatitis (AD)

Phase 1

Clinical Trials (1)

NCT07453602Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Phase 1

ARQ-151 cream 0.15%

Atopic Dermatitis (Eczema)

Phase 1

Clinical Trials (2)

NCT04804605Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Phase 3

NCT04156191Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

ARQ-151- cream 0.3%

Plaque Psoriasis

Phase 1

Clinical Trials (1)

NCT04279119Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis

Phase 1

roflumilast

Atopic Dermatitis

Phase 1

ARQ-151 cream 0.5%

Psoriasis

Phase 1/2

Clinical Trials (1)

NCT03392168Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Phase 1/2

ARQ-252 cream 0.3%

Chronic Hand Eczema

Phase 1/2

Clinical Trials (1)

NCT04378569Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Phase 1/2

ARQ-154

Seborrheic Dermatitis

Phase 2

Clinical Trials (4)

NCT04973228Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Phase 3

NCT04091646Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

ARQ-252 cream 0.3%

Vitiligo

Phase 2

Clinical Trials (1)

NCT04811131Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Phase 2

PDE4 inhibitor

Chronic Hand Eczema

Phase 2

ARQ-151 cream 0.3%

Psoriasis

Phase 2

Clinical Trials (1)

NCT04746911Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Phase 2

ARQ-151 cream 0.3%

Psoriasis

Phase 2

Clinical Trials (1)

NCT04655313Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Phase 2

roflumilast

Plaque Psoriasis

Phase 3

Clinical Trials (5)

NCT07560618Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

Phase 4

NCT04773600Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

roflumilast

Seborrheic Dermatitis

Phase 3

Interview Prep Quick Facts

Founded: 2016

Portfolio: 2 approved products, 29 clinical trials

Top TAs: Immunology, Dermatology, Gastroenterology

Publications: 30 in PubMed

SEC Filings: 2 available

Open Roles: 7 active jobs

Portfolio Health

Growth1 (50%)

Peak1 (50%)

2 total products

Therapeutic Area Focus

Immunology

2 marketed22 pipeline

7 pipeline

2 marketed

2 marketed

2 marketed

Financials (FY2025)

Revenue

$60M1517%

R&D Spend

$111M(186%)39%

Net Income

-$262M

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

The Journal of dermatological treatment

2026

PMID:42274146

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

NCT04445987Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Phase 2

NCT04286607Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Phase 3

Respiratory

2 marketed

Psychiatry

1 marketed

The Journal of dermatological treatment

2026

PMID:42274139

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Arcutis Biotherapeutics(ARQT)

Should You Work at Arcutis Biotherapeutics?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Recent News · Arcutis Biotherapeutics(10)

Open Jobs (7)

Overlay Therapeutic Sales Specialist - Inland Empire

Primary Care High Value Specialist

Therapeutic Sales Specialist - Worcester, MA

Overlay Therapeutic Sales Specialist - Long Island, NY

Regional Sales Director - South Florida

Therapeutic Sales Specialist - Brooklyn, NY

Therapeutic Sales Specialist - Arlington, VA

Financials (FY2025)

Hiring Trend

Research Publications(10)